Danone (DN) Q4 2024 earnings summary

Executive summary

• Achieved 4.3% like-for-like sales growth in FY 2024, with all regions and categories contributing positively to volume/mix and growth quality.

• Recurring operating margin improved by 39 basis points to 13.0%, with recurring EPS up 2.5% to €3.63 and record free cash flow of €3.0bn, supported by strong working capital management.

• ROIC returned to double digits, reaching 10% for the first time since 2016.

• Broad-based growth across all categories and geographies, with strong momentum in health-focused and innovation-driven products.

• Continued reinvestment in brands, R&D, digital health, and operational excellence, with a focus on sustainability and digital transformation.

Financial highlights

• FY 2024 net sales reached €27,376m, with reported sales down 0.9% due to negative forex and scope effects, despite strong like-for-like growth.

• Recurring operating income rose to €3,558m, recurring operating margin at 13.0% (+39 bps year-over-year).

• Recurring EPS increased to €3.63 (+2.5%), and free cash flow hit a record €3.0bn, up 14% year-over-year.

• Net debt reduced to €8.6bn (Net debt/EBITDA: 1.9x), supported by strong free cash flow.

• Proposed dividend of €2.15 per share, up 2.4%, with a 59% payout ratio.

Outlook and guidance

• 2025 guidance targets like-for-like sales growth of +3% to +5%, with recurring operating income expected to grow faster than sales.

• Expecting normalized commodity cost inflation in 2025, mainly from milk and packaging, with targeted, consumer-led pricing actions.

• Share buyback of 2.7 million shares planned in 2025 to offset dilution from employee plans.

• Continued focus on productivity, operational leverage, and reinvestment in growth drivers.